Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials

ClinicalLIVEUpdated 18 Nov 2026

New Clinical Trials

Clinical trials companies registered in the last 30 days, worldwide, with the sponsor, phase and countries.

Sources: ClinicalTrials.gov · Rebuilt weekly · Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase.

Trials
777
in the 30 days to 2026-11-18
Added in 30 days
777
to 18 Nov 2026
Top country
United States
192 · 25% of the list
Phase covered
8
distinct values
Snapshot · 18 Nov 2026
Explore all 777

Signals

What the register says this week, and why it matters if you sell into it.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
  3. 174 of the listed studies are device, diagnostic or digital-health studies (no drug phase).
  4. A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

Export the full new clinical trials

777 rows as a .csv. Free. Every field, with its source link.

Country
Phase 1
Study type
97 / 777 trials
PostedSponsorStudyPhaseStatus
4 Nov 2026Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.ChinaA Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients.Phase 3Not Yet Recruiting3 Nov 2026Genfleet Therapeutics (Shanghai) Inc.GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal CancerPhase 3Not Yet Recruiting3 Nov 2026HutchmedHMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 MutationsPhase 3Not Yet Recruiting3 Nov 2026Jiangsu Hansoh Pharmaceutical Co., Ltd.ChinaPhase 3 Study of HS-10380 for Acute Schizophrenia in Chinese AdultsPhase 3Not Yet Recruiting3 Nov 2026Jiangsu HengRui Medicine Co., Ltd.ChinaA Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal InsulinPhase 3Not Yet Recruiting3 Nov 2026MIBIO PTE. LTD.GeorgiarhTPO for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Procedures.Phase 3Recruiting2 Nov 2026AstraZenecaA Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Phase 3Not Yet Recruiting2 Nov 2026Guangzhou Patronus Biotech Co., Ltd.ChinaA Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and OlderPhase 3Not Yet Recruiting2 Nov 2026Keymed Biosciences Co.LtdChinaStudy of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple MyelomaPhase 3Not Yet Recruiting2 Nov 2026Merck Sharp & Dohme LLCA Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)Phase 3Not Yet Recruiting30 Oct 2026Boehringer IngelheimUnited States, Italy, MalaysiaThe AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary DiseasePhase 3Not Yet Recruiting30 Oct 2026Janssen Research & Development, LLCUnited States, IsraelA Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate CancerPhase 3Recruiting29 Oct 2026Enliven TherapeuticsUnited StatesA Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIsPhase 3Recruiting29 Oct 2026Inmunotek S.L.Portugal, SpainSpecific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-069.Phase 3Recruiting29 Oct 2026Inmunotek S.L.Portugal, SpainSpecific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.Phase 3Recruiting29 Oct 2026Jade Biosciences, Inc.United StatesA Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyPhase 3Recruiting29 Oct 2026Janssen Research & Development, LLCA Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant EligiblePhase 3Not Yet Recruiting29 Oct 2026Kite, A Gilead CompanyTo Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaPhase 3Not Yet Recruiting29 Oct 2026Shanghai Huaota Biopharmaceutical Co., Ltd.ChinaHB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial CancerPhase 3Recruiting29 Oct 2026Shanghai Mabgeek Biotech.Co.LtdA Study to Evaluate the Efficacy and Safety of MG-K10 in Adults With Chronic Rhinosinusitis With Nasal PolypsPhase 3Not Yet Recruiting28 Oct 2026Eli Lilly and CompanyUnited States, Argentina, AustraliaA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskPhase 3Not Yet Recruiting28 Oct 2026Laboratorios Silanes S.A. de C.V.MexicoStudy to Evaluate the Efficacy and Safety of Dexketoprofen / Butylscopolamine vs Dexketoprofen in Treatment of Primary DysmenorrheaPhase 3Completed28 Oct 2026Precigen, IncUnited StatesZopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in ChildrenPhase 3Not Yet Recruiting28 Oct 2026Regeneron PharmaceuticalsLinvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain AmyloidosisPhase 3Not Yet Recruiting28 Oct 2026Shanghai Hengrui Pharmaceutical Co., Ltd.ChinaHRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic CancerPhase 3Not Yet Recruiting27 Oct 2026AbbVieA Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental VitiligoPhase 3Not Yet Recruiting27 Oct 2026Amneal Pharmaceuticals, LLCUnited StatesSafety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With HypogonadismPhase 3Recruiting27 Oct 2026Beijing InnoCare Pharma Tech Co., Ltd.ChinaOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone LymphomaPhase 3Not Yet Recruiting27 Oct 2026Hanmi Pharmaceutical Company LimitedSouth KoreaA Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction PatientsPhase 3Recruiting27 Oct 2026Jiangsu Aosaikang Pharmaceutical Co., Ltd.ChinaASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLCPhase 3Not Yet Recruiting27 Oct 2026Swedish Orphan BiovitrumBrazil, Canada, FinlandA Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant RecipientsPhase 3Recruiting26 Oct 2026Jiangsu HengRui Medicine Co., Ltd.ChinaA Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast CancerPhase 3Not Yet Recruiting26 Oct 2026Qilu Pharmaceutical Co., Ltd.QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine CarcinomaPhase 3Not Yet Recruiting26 Oct 2026Regeneron PharmaceuticalsEfficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without DiabetesPhase 3Not Yet Recruiting26 Oct 2026Suzhou Suncadia Biopharmaceuticals Co., Ltd.ChinaSHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III StudyPhase 3Not Yet Recruiting26 Oct 2026Suzhou Suncadia Biopharmaceuticals Co., Ltd.ChinaA Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung CancerPhase 3Not Yet Recruiting22 Oct 2026Hoffmann-La RocheA Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering MedicationsPhase 3Not Yet Recruiting22 Oct 2026Pathalys PharmaUnited StatesA Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisPhase 3Not Yet Recruiting22 Oct 2026PfizerA Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast CancerPhase 3Not Yet Recruiting22 Oct 2026SanofiPolandStudy of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and OlderPhase 3Recruiting22 Oct 2026ScandiBio Therapeutics ABTurkey (Türkiye)Combined Metabolic Activator Supplementation in Subjects Diagnosed With GoutPhase 3Not Yet Recruiting22 Oct 2026Vertex Pharmaceuticals IncorporatedUnited StatesA Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringePhase 3Recruiting21 Oct 2026Jiangsu Hansoh Pharmaceutical Co., Ltd.ChinaA Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPPhase 3Not Yet Recruiting21 Oct 2026Kite, A Gilead CompanyA Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaPhase 3Not Yet Recruiting21 Oct 2026PfizerA Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older AdultsPhase 3Not Yet Recruiting21 Oct 2026WockhardtBosnia and Herzegovina, Bulgaria, CroatiaCefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaPhase 3Not Yet Recruiting20 Oct 2026Waterstone Pharmaceutical (Wuhan) Co., LTD.ChinaA Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of HyperkalemiaPhase 3Recruiting

// How AOS uses this

Every row here is a potential account. AOS finds the ones that need what you sell, maps the decision makers and prepares the outreach for your approval.